OptiNose

OptiNose ROA

Delisted

The Return on Assets (ROA) of OptiNose (OPTN) as of Nov 11, 2026 is -16.73 %. In the previous year, Return on Assets (ROA) was -32.94 % — a change of -49.22% (higher).

ROA

-16.73 %

YoY

-49.22%

Last updated:

In 2024, OptiNose's return on assets (ROA) was -16.73 %, a -49.22% increase from the -32.94 % ROA in the previous year.

The OptiNose ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2017
-20.28 USD
Jan 1, 2018
-49.15 USD
Jan 1, 2019
-63.10 USD
Jan 1, 2020
-52.08 USD
Jan 1, 2021
-49.17 USD
Jan 1, 2022
-52.97 USD
Jan 1, 2023
-32.94 USD
Jan 1, 2024
-16.73 USD
The OptiNose ROA history
YEARROAYoY
-16.73 %-49.22%
-32.94 %-37.82%
-52.97 %+7.74%
-49.17 %-5.59%
-52.08 %-17.47%
-63.10 %+28.38%
-49.15 %+142.38%
-20.28 %-137.26%
54.42 %-130.77%
-176.86 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

ROA Details

Understanding OptiNose's Return on Assets (ROA)

OptiNose's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing OptiNose's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider OptiNose's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in OptiNose’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about OptiNose stock

Return on Assets (ROA) of OptiNose is -16.73 % in 2024.

Return on Assets (ROA) of OptiNose changed from -32.94 % to -16.73 %, representing a -49.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) OptiNose since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s OptiNose with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OptiNose

All Key Metrics — OptiNose